Recently, several members of the Blue Matter leadership team gathered in the oscillating climes of Philadelphia for the 2026 Informa Rare Disease Summit. Despite one very early morning emergency alarm that served as a collective wake-up call for the entire hotel, the experience was highly rewarding. We left the summit reflecting on a core truth: while data and technology are evolving rapidly, a patient-centric, individualized approach remains the critical foundation for success in rare disease commercialization.

As we move further into 2026, four high-impact themes emerged from the summit that are top-of-mind for rare disease leaders.

Takeaway #1: Moving Beyond the “Average” – Data with a Human Touch

Historically, rare disease companies focused predominantly on patient finding and accelerating diagnosis. However, as these markets mature, there is an increasing need to focus across the entire patient journey.

  • Precision in Patient Finding: Successful pre-launch strategies now combine AI-augmented datasets with the “human touch” (using field teams and “feet on the ground” at conferences to build relationships and fill the patient funnel).
  • Addressing Post-Launch Friction: Approval and demand are no longer enough. Patients often get stuck in the access process, and data can help identify and address their specific pain points.
  • The Trap of the “Average”: In rare disease, with small patient populations (small n), focusing on the “average” can be dangerous. An acceptable average may mask the fact that a significant percentage of patients are falling far below the goal, hiding barriers that require actionable, individualized solutions.

Takeaway #2: Strategic Value of the Patient and Caregiver Voice

A common thread across sessions—from competitive strategy to regulatory excellence—was the continued importance of the patient voice. It is no longer just a checkbox; it is a strategic differentiator.

  • Clinical Trial Design: Integrating the patient voice helps minimize barriers to recruitment and retention while ensuring pivotal data is meaningfully differentiated.
  • Regulatory Success: A retrospective on Sarepta’s journey with etiplersen highlighted that qualitative data detailing the therapy’s impact on individual lives is just as critical as clinical metrics and was key in discussions with the FDA. Panelists emphasized that Quality of Life (QoL) data should be robustly designed, not merely anecdotal.
  • Payer Conversations: Shifting away from “templated” formats to focus on the real-world impact for the patient can help form the foundation of more meaningful coverage discussions for small populations.

Takeaway #3: Authentic Advocacy – Building Partnerships Through Transparency

Strong relationships with Patient Advocacy Organizations (PAOs) are essential, but the summit highlighted that these relationships must be built on end-to-end transparency.

  • The “Dating” Metaphor: Advocacy relationships should be “clear and human,” almost like dating. This means being honest about what both parties are looking for and recognizing that different PAOs have various levels of experience and trust with pharma.
  • Early Engagement: Companies should engage PAOs early, even when just considering a disease area through R&D or business development.
  • Sharing Difficult News: In the event of a trial failure (for example), the PAO should be among the first to know. Scheduling a call immediately after an investor update to explain what went wrong and what happens next is vital for maintaining long-term trust. As the rare disease space has grown more crowded and regulatory scrutiny of patient-reported outcomes has intensified, PAOs have become genuinely consequential stakeholders in both trial design and market access, which means the cost of a damaged relationship has never been higher

Takeaway #4: AI as an Accelerator, Humans as the Heart

Artificial Intelligence was a strong presence at the summit, particularly regarding its potential to accelerate the repurposing of “shelved” products and connect interested parties with discarded assets.  Specifically, AI-driven tools are enabling more sophisticated matching of existing molecular profiles against emerging disease insights, surfacing candidates that may have failed in one indication but hold real promise in rare disease contexts where unmet need is high and patient populations are distinct. This emerging capability could help broker connections between asset holders and rare disease developers who might never have found each other through traditional channels.

However, the consensus among our team was that in the rare disease space, humans need to be more than just “in-the-loop”. Because of the unique emotional and clinical complexities of most rare conditions, humans must be the beginning, middle, and end of the “rollercoaster” that is the rare disease journey.

At Blue Matter, we remain committed to helping our clients navigate the complex commercial and strategic landscape of rare diseases.  If you would like to discuss how trends in the rare disease space or the themes outlined in this article might impact your portfolio, then please contact us today.